WallStSmart

AbbVie Inc (ABBV)vsPrestige Brand Holdings Inc (PBH)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AbbVie Inc generates 5727% more annual revenue ($64.39B vs $1.10B). PBH leads profitability with a 15.6% profit margin vs 9.8%. ABBV appears more attractively valued with a PEG of 0.52. ABBV earns a higher WallStSmart Score of 73/100 (B).

ABBV

Strong Buy

73

out of 100

Grade: B

Growth: 6.7Profit: 8.5Value: 4.0Quality: 5.0
Piotroski: 5/9Altman Z: 0.40

PBH

Buy

59

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 4.7Quality: 6.5
Piotroski: 2/9Altman Z: 2.06
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABBVSignificantly Overvalued (-69.4%)

Margin of Safety

-69.4%

Fair Value

$151.82

Current Price

$257.12

$105.30 premium

UndervaluedFair: $151.82Overvalued
PBHSignificantly Overvalued (-52.5%)

Margin of Safety

-52.5%

Fair Value

$43.25

Current Price

$46.95

$3.70 premium

UndervaluedFair: $43.25Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABBV6 strengths · Avg: 9.7/10
Market CapQuality
$454.36B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
62.3%10/10

Every $100 of equity generates 62 in profit

Operating MarginProfitability
40.0%10/10

Strong operational efficiency at 40.0%

EPS GrowthGrowth
290.4%10/10

Earnings expanding 290.4% YoY

Debt/EquityHealth
-11.9310/10

Conservative balance sheet, low leverage

PEG RatioValuation
0.528/10

Growing faster than its price suggests

PBH3 strengths · Avg: 8.7/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

P/E RatioValuation
13.6x8/10

Attractively priced relative to earnings

Operating MarginProfitability
20.8%8/10

Strong operational efficiency at 20.8%

Areas to Watch

ABBV2 concerns · Avg: 2.0/10
P/E RatioValuation
72.0x2/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
0.402/10

Distress zone — elevated risk

PBH4 concerns · Avg: 3.0/10
PEG RatioValuation
1.524/10

Expensive relative to growth rate

Debt/EquityHealth
1.083/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-35.8%2/10

Earnings declined 35.8%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABBV

The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 10.2% demonstrates continued momentum. PEG of 0.52 suggests the stock is reasonably priced for its growth.

Bull Case : PBH

The strongest argument for PBH centers on Price/Book, P/E Ratio, Operating Margin. Profitability is solid with margins at 15.6% and operating margin at 20.8%.

Bear Case : ABBV

The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 72.0x leaves little room for execution misses.

Bear Case : PBH

The primary concerns for PBH are PEG Ratio, Debt/Equity, Piotroski F-Score.

Key Dynamics to Monitor

ABBV profiles as a value stock while PBH is a mature play — different risk/reward profiles.

PBH carries more volatility with a beta of 0.33 — expect wider price swings.

ABBV is growing revenue faster at 10.2% — sustainability is the question.

ABBV generates stronger free cash flow (3.2B), providing more financial flexibility.

Bottom Line

ABBV scores higher overall (73/100 vs 59/100) and 10.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

AbbVie Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.

Prestige Brand Holdings Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Prestige Consumer Healthcare Inc., develops, manufactures, markets, distributes and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company is headquartered in Tarrytown, New York.

Want to dig deeper into these stocks?